SAN FRANCISCO, Feb. 21, 2020 (GLOBE NEWSWIRE) — 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases,… […]
SOUTH SAN FRANCISCO, Calif., Feb. 21, 2020 (GLOBE NEWSWIRE) — Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral dis… […]
Gilead sustained two more losses in their efforts to rid themselves of an activist-backed patent lawsuit from the US government over a best-selling HIV pill.
Urged on by activists seeking to divert a portion of Gilead’s revenue to clinics and preventio… […]
Grifols once paid Aradigm $26 million for a stake in its inhaled antibiotics. But with Aradigm now in bankruptcy, the Spanish drugmaker is dishing out a final $3.2 million to buy it all.
The fire sale — which comes one year after Aradigm filed for Chap… […]
→ Seasoned drug hunter Siegfried Reich has left eFFECTOR, the biotech he co-founded to discover selective translation regulators, to take up the CSO role at Turning Point Therapeutics.
“I have followed the progress Turning Point has made, and was drawn… […]
A narrow band of proteins that run through dozens of food allergies helped a Peninsula startup swallow $60 million from a syndicate of investors — including high-powered families — to develop a broad food allergy treatment.
Alladapt Immunotherapeutics… […]
Since a major restructuring at Five Prime Therapeutics in October that kicked off a wind-down of most of its research and preclinical efforts, the company has been looking to add to its partnerships portfolio. On Wednesday, South San Francisco-based Fi… […]